Home  |  Contact

Cellosaurus SUM229PE (CVCL_5594)

[Text version]

Cell line name SUM229PE
Synonyms SUM-229PE; SUM 229PE; SUM-229; SUM 229; SUM229; 229PE
Accession CVCL_5594
Resource Identification Initiative To cite this cell line use: SUM229PE (RRID:CVCL_5594)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Problematic cell line: Partially misidentified. For a period of time Asterand (now BioIVT) mistakenly distributed SUM149PT (CVCL_3422) under the designation of SUM229PE. This leads to the publication of a STR profile (PubMed=25877200) which was almost identical to that of SUM149PT.
Part of: GrayJW breast cancer cell line panel.
Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00548.
Doubling time: 42.27 hours (https://www.synapse.org/#!Synapse:syn2347014).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: Glycoproteome analysis by proteomics.
Omics: miRNA expression profiling.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Homozygous for CDKN2A deletion (PubMed=19593635).
Heterozygous for KRAS p.Gly12Asp (c.35G>A) (ClinVar=VCV000012582) (PubMed=19593635; DepMap).
TP53 p.Arg273Cys (c.817C>T) (ClinVar=VCV000043594) (PubMed=16541312; DepMap).
HLA typing Source: PubMed=25960936
Class I
HLA-AA*02:01,11:01
HLA-BB*44:02,40:02
HLA-CC*03:04,02:02
Class II
HLA-DQDQB1*05:01,05:01
HLA-DRDRB1*01:01,15:01
Disease Breast carcinoma (NCIt: C4872)
Derived from metastatic site: Pleural effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): BioIVT/Asterand

Markers:
AmelogeninX
CSF1PO10,11
D5S8189,12
D7S8208,9
D13S31712
D16S53911,13
TH019.3
TPOX8,9
vWA18,19

Run an STR similarity search on this cell line
Web pages https://sumlineknowledgebase.com/?page_id=295
https://bioivt.com/sum-breast-cancer-cell-lines/
https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
http://iclac.org/wp-content/uploads/Cross-Contaminations_v10_distribution.xlsx
Publications

PubMed=10424408; DOI=10.1023/A:1006135331912
Ignatoski K.M.W., Ethier S.P.
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.
Breast Cancer Res. Treat. 54:173-182(1999)

PubMed=10604729; DOI=10.1038/sj.bjc.6695007
Forozan F., Veldman R., Ammerman C.A., Parsa N.Z., Kallioniemi A., Kallioniemi O.-P., Ethier S.P.
Molecular cytogenetic analysis of 11 new breast cancer cell lines.
Br. J. Cancer 81:1328-1334(1999)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=16541312; DOI=10.1007/s10549-006-9186-z
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Breast Cancer Res. Treat. 99:97-101(2006)

PubMed=19593635; DOI=10.1007/s10549-009-0460-8
Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
Breast Cancer Res. Treat. 121:53-64(2010)

PubMed=21778573; DOI=10.3233/BD-2010-0307
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

PubMed=23401782; DOI=10.1155/2013/872743
Barnabas N., Cohen D.
Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines.
Int. J. Breast Cancer 2013:872743-872743(2013)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33-R33(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J., Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:E954893-E954893(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
J. Proteome Res. 16:1391-1400(2017)

Cross-references
Cell line databases/resources Cell_Model_Passport; SIDM01461
DepMap; ACH-001394
LINCS_HMS; 51086
LINCS_LDP; LCL-2065
Ontologies BTO; BTO:0005479
EFO; EFO_0006762
Biological sample resources BioSample; SAMN03471035
Chemistry resources PharmacoDB; SUM229PE_1512_2019
Gene expression databases ArrayExpress; E-MTAB-2706
GEO; GSM421892
GEO; GSM1172996
GEO; GSM1172902
Other Wikidata; Q54970849
Polymorphism and mutation databases Cosmic; 904393
Cosmic; 997923
Cosmic; 1046949
Cosmic; 1287930
Cosmic; 1289416
Cosmic; 1460243
Cosmic; 1479523
IARC_TP53; 24363
Proteomic databases PRIDE; PXD005295
Entry history
Entry creation04-Apr-2012
Last entry update02-Jul-2020
Version number26